Showing 6621-6630 of 8198 results for "".
- Study: Knowledge of Skin Cancer Risk May Limit Tanning Bed Use, Unhealthy Behaviorshttps://practicaldermatology.com/news/study-knowledge-of-skin-cancer-risk-may-limit-tanning-bed-use-unhealthy-behaviors/2461064/When patients know their risk for skin cancer, they may change their behaviors to lower their chances of developing melanoma, a new study suggests. A recent
- Merz Aesthetics Launches Radiesse (+) as First and Only Aesthetic Injectable to Improve Moderate to Severe Loss of Jawline Contourhttps://practicaldermatology.com/news/merz-aesthetics-launches-radiesse-as-first-and-only-aesthetic-injectable-to-improve-moderate-to-severe-loss-of-jawline-contour/2461062/Merz Aesthetics is launching Radiesse (+) Lidocaine for jawline contouring in adults over the age of 21. Radiesse (+) is the first and only U.S. Food and Drug Administration (FDA)-approved injectable treatment for jawline contour improvement. The FDA approved the supplemental
- FDA Accepts Label Update for Suneva’s Plasma IQhttps://practicaldermatology.com/news/fda-accepts-label-update-for-sunevas-plasma-iq/2461061/Plasma IQ label, including the removal of the product's eye contraindication. The removal of this specific contraindication was due in part to a compilation of literature provided to the FDA showing the safety and efficacy of the ablative device on skin tissue, particular
- New Guidelines from AAD Address Comorbidities of ADhttps://practicaldermatology.com/news/new-guidelines-from-aad-address-comorbidities-of-ad/2461060/New guidelines released this week by the American Academy of Dermatology (AAD)
- Skyrizi Gets Psoriatic Arthritis Indicationhttps://practicaldermatology.com/news/skyrizi-gets-psoriatic-arthritis-indication/2461049/Skyrizi® (risankizumab-rzaa) from AbbVie is now approved for the treatment of adults with active psoriatic arthritis (PsA). FDA approval is supported by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated the efficacy a
- Vial to Host Advisory Boardhttps://practicaldermatology.com/news/vial-to-host-advisory-board/2461038/Vial is hosting an Advisory Board with leading research sites to discuss the challenges in clinical research. Launched in conjunction with the 2022 Winter Clinical Dermatology conference, the meeting will focus on improving speed and quality of trials in dermatology. The Vial executive
- FDA Approves Pfizer's Cibinqo for Moderate-to-Severe AD in Adultshttps://practicaldermatology.com/news/fda-approves-pfizers-cibinqo-for-moderate-to-severe-ad-in-adults/2461037/Pfizer's Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, is now FDA approved for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including bi
- FDA Approves Rinvoq for Adults and Children 12 Years and Older with Refractory, Moderate to Severe ADhttps://practicaldermatology.com/news/us-fda-approves-rinvoq-for-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-ad/2461036/The FDA has given its nod to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including bio
- BTL Introduces EMFACE Technologyhttps://practicaldermatology.com/news/btl-introduces-emface-technology/2461033/Described as the result of many years of institutional knowledge of the simultaneous emission of radio frequency and electromagnetic energies, EMFACE™ is the newest innovation from BTL. It utilizes a patented technology of muscle contraction and skin tissue heating. &quo
- Galderma Completes Alastin Acquisitionhttps://practicaldermatology.com/news/galderma-completes-alastin-acquisition/2461026/Having received antitrust clearance from US authorities, Galderma has completed the acquisition of Alastin Skincare®, Inc., a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispens